Cite

HARVARD Citation

    Tryggestad, A. et al. (2022). Long‐term first‐in‐man Phase I/II study of an adjuvant dendritic cell vaccine in patients with high‐risk prostate cancer after radical prostatectomy. Prostate. 82 (2), pp. 245-253. [Online]. 
  
Back to record